Janux Therapeutics (JANX) Current Deferred Revenue (2020 - 2024)
Historic Current Deferred Revenue for Janux Therapeutics (JANX) over the last 5 years, with Q2 2024 value amounting to $94000.0.
- Janux Therapeutics' Current Deferred Revenue fell 9823.97% to $94000.0 in Q2 2024 from the same period last year, while for Jun 2024 it was $94000.0, marking a year-over-year decrease of 9823.97%. This contributed to the annual value of $1.7 million for FY2023, which is 6846.1% down from last year.
- Latest data reveals that Janux Therapeutics reported Current Deferred Revenue of $94000.0 as of Q2 2024, which was down 9823.97% from $972000.0 recorded in Q1 2024.
- Janux Therapeutics' Current Deferred Revenue's 5-year high stood at $8.0 million during Q4 2020, with a 5-year trough of $94000.0 in Q2 2024.
- Over the past 5 years, Janux Therapeutics' median Current Deferred Revenue value was $5.1 million (recorded in 2021), while the average stood at $4.4 million.
- In the last 5 years, Janux Therapeutics' Current Deferred Revenue surged by 1219.6% in 2022 and then tumbled by 9823.97% in 2024.
- Quarter analysis of 5 years shows Janux Therapeutics' Current Deferred Revenue stood at $8.0 million in 2020, then plummeted by 35.46% to $5.2 million in 2021, then increased by 4.71% to $5.4 million in 2022, then tumbled by 68.46% to $1.7 million in 2023, then crashed by 94.49% to $94000.0 in 2024.
- Its last three reported values are $94000.0 in Q2 2024, $972000.0 for Q1 2024, and $1.7 million during Q4 2023.